Company: SRPT
Filing Date: 2025-07-16
Form Type: 8-K
Source: 0000950170-25-096257
Chunk: 1

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-07-16
Form: 8-K
Item: Item 5.02
Chunk 1
---
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 14, 2025, the Board appointed Ian Estepan as the Company’s President and Chief Operating Officer, Louise Rodino-Klapac, Ph. D. as the Company’s President, Research and Development and Technical Operations, and Ryan Wong as the Company’s Executive Vice President, Chief Financial Officer, each effective as of July 16, 2025. Douglas Ingram, who previously served as the Company’s President and Chief Executive Officer, will continue to serve as the Company’s Chief Executive Officer. Mr. Wong will replace Mr. Estepan as the Company’s principal financial officer and principal accounting officer.

Mr. Estepan has served as the Company’s Executive Vice President, Chief Financial Officer since December 2020. Mr. Estepan joined the Company in January 2015 as Senior Director, Corporate Affairs. From October 2016 to December 2017, he served as Executive Director, Corporate Affairs; from January 2018 to February 2019, he served as Vice President, Chief of Staff and Corporate Affairs; and from February 2019 to December 2020, he served as Senior Vice President, Chief of Staff and Corporate Affairs. Since November 2021, Mr. Estepan has served on the Board of Directors for Cellarity, a private biopharmaceutical company. Mr. Estepan currently serves as Executive Chairman of AbBC Therapies, a private biopharmaceutical company. Prior to joining the Company, Mr. Estepan managed a portfolio on the buyside at Spectra Financial Group for 15 years, overseeing a portfolio of pharmaceutical, biotech and medtech equities. Mr. Estepan received his Bachelor of Arts in psychology with a concentration in pre-medicine from Columbia University.

In connection with his appointment and expanded responsibilities, Mr. Estepan’s base salary will be increased to $800,000 and his target bonus will be increased to 65% of his base salary.

Dr. Rodino-Klapac has served as the Company’s Executive Vice President, Chief Scientific Officer since December 2020. Dr. Rodino-Klapac was additionally appointed as our Head of R& D in November 2021. Dr. Rodino-Klapac joined the Company as Vice President, Gene Therapy in April 2018. From February 2019 to December